Use, survival, and adverse events of dostarlimab monotherapy in advanced or recurrent endometrial cancer: a nationwide cohort study in France
Abstract Dostarlimab, a PD-1 inhibitor, was approved in Europe as monotherapy for patients with advanced or recurrent mismatch repair-deficient endometrial cancer, based on the phase I GARNET study. As real-world data remain limited, this study aimed to describe the characteristics and survival outcomes of patients tre...